Evidence map›Paper›PMID 27166943›Full record

ReviewCell metabolism2016

Modifying the Mitochondrial Genome.

Alexander N Patananan, Ting-Hsiang Wu, Pei-Yu Chiou, Michael A Teitell

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell metabolism, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 114 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Molecular mechanisms of mitochondrial quality control.Translational neurodegeneration · 2025
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Extracellular Delivery of Functional Mitochondria Rescues the Dysfunction of CD4Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Alexander N PatanananDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Ting-Hsiang WuNantWorks, LLC, Culver City, CA 90232, USA.
Pei-Yu ChiouDepartment of Mechanical and Aerospace Engineering, University of California, Los Angeles, Los Angeles, CA 90095, USA; California NanoSystems Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Michael A TeitellDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; California NanoSystems Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address: mteitell@ucla.edu.
Broad Center · USCalifornia NanoSystems Institute · USNantWorks (United States) · USUniversity of California, Los Angeles · US

Funding

UCLA Tumor Immunology Training ProgramT32CA009120 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Steven M. Dubinett, MICHAEL A TEITELL · 1985 to 2026
$10.3M
RNA trafficking in mitochondriaR01GM073981 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Carla M Koehler, MICHAEL A TEITELL · 2006 to 2026
$5.1M
TCL1 ONCOGENE IN B LYMPHOCYTE DEVELOPMENT AND NEOPLASIAR01CA090571 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TEITELL, MICHAEL A · 2002 to 2015
$3.8M
(PQD5) Mass Profiling Melanoma Responses to Improve Therapy Choices and PrognosisR01CA185189 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REED, JASON C, TEITELL, MICHAEL A · 2014 to 2017
$1.9M
Reverse Mitochondrial Genetics Enabled by BlastR01GM114188 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHIOU, PEI-YU, TEITELL, MICHAEL A · 2015 to 2018
$1.9M
A Fourth Outcome: DNA Damage and the Differentiation of B CellsR01CA156674 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TEITELL, MICHAEL A · 2011 to 2015
$1.5M
NCI NIH HHS R01 CA090571NCI NIH HHS R01 CA156674NCI NIH HHS R01 CA185189NCI NIH HHS T32 CA009120NIGMS NIH HHS R01 GM073981NIGMS NIH HHS R01 GM114188
6 · The paper itself

Abstract

Human mitochondria produce ATP and metabolites to support development and maintain cellular homeostasis. Mitochondria harbor multiple copies of a maternally inherited, non-nuclear genome (mtDNA) that encodes for 13 subunit proteins of the respiratory chain. Mutations in mtDNA occur mainly in the 24 non-coding genes, with specific mutations implicated in early death, neuromuscular and neurodegenerative diseases, cancer, and diabetes. A significant barrier to new insights in mitochondrial biology and clinical applications for mtDNA disorders is our general inability to manipulate the mtDNA sequence. Microinjection, cytoplasmic fusion, nucleic acid import strategies, targeted endonucleases, and newer approaches, which include the transfer of genomic DNA, somatic cell reprogramming, and a photothermal nanoblade, attempt to change the mtDNA sequence in target cells with varying efficiencies and limitations. Here, we discuss the current state of manipulating mammalian mtDNA and provide an outlook for mitochondrial reverse genetics, which could further enable mitochondrial research and therapies for mtDNA diseases.

Indexed as

Genome, MitochondrialAnimalsDNA, MitochondrialHumansMicroinjectionsMitochondriaNuclear Transfer TechniquesReverse GeneticsDNA, Mitochondrial

Identifiers

PMID27166943
PMCPMC4864607
OpenAlexW2360183543

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.